SEC 13F Intelligence

Managers / Q1 2022 · view latest →

TRV GP III, LLC

CIK 0001637299 · THIRD ROCK VENTURES, 201 BROOKLINE AVE, SUITE 1401, BOSTON, MA, 02215 · (617)585-2000

Reported Value
$369M
Q1 2022
Positions
7
Filings on Record
21
2019–present window
Filed
May 10, 2022
original filing

Summary

Trv GP III, LLC reported $369M in U.S.-listed holdings across 7 positions for Q1 2022.

The portfolio is heavily concentrated: RVMD alone accounts for 38.2% of reported value.

The book was largely unchanged from Q4 2021.

Portfolio Metrics

Turnover
+14.8%
vs prior filed quarter
Largest Position
+38.2%
Revolution Medicines

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $119MQ4 ’18Q1 ’19: $204MQ2 ’19: $235MQ3 ’19: $176MQ3 ’19Q4 ’19: $226MQ1 ’20: $368MQ2 ’20: $685MQ2 ’20Q3 ’20: $1.2BQ4 ’20: $1.2BQ1 ’21: $791MQ1 ’21Q2 ’21: $573MQ3 ’21: $527MQ4 ’21: $400MQ4 ’21Q1 ’22: $369MQ2 ’22: $244MQ3 ’22: $229MQ3 ’22Q4 ’22: $128MQ1 ’23: $83MQ2 ’23: $18MQ2 ’23Q3 ’23: $6MQ4 ’23: $6Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 97.4%Other: 2.6%
  • Common Stock · 97.4% · $359M
  • Other · 2.6% · $10M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
NRIXNURIX THERAPEUTICS, INC.TRIMMED−500.0K1.92M−$43M$27M
PLRXPLIANT THERAPEUTICS, INC.HELD+05.84M−$38M$41M
VYGRVOYAGER THERAPEUTICS, INC.HELD+06.39M+$31M$49M
FULCFULCRUM THERAPEUTICS, INC.HELD+03.96M+$24M$94M
DECIBEL THERAPEUTICS, INC.HELD+03.14M−$5M$10M
RVMDREVOLUTION MEDICINES, INC.HELD+05.52M+$2M$141M
JNCEEURJOUNCE THERAPEUTICS, INC.HELD+01.15M−$2M$8M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2022

7 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1RVMDREVOLUTION MEDICINES, INC.history →COM38.24%$141M5.52M
2FULCFULCRUM THERAPEUTICS, INC.history →COM25.43%$94M3.96M
3VYGRVOYAGER THERAPEUTICS, INC.history →COM13.21%$49M6.39M
4PLRXPLIANT THERAPEUTICS, INC.history →COM11.11%$41M5.84M
5NRIXNURIX THERAPEUTICS, INC.history →COM7.31%$27M1.92M
6DECIBEL THERAPEUTICS, INC.COM2.59%$10M3.14M
7JNCEEURJOUNCE THERAPEUTICS, INC.history →COM2.12%$8M1.15M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2023$6M1Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$6M1Nov 13, 202313F-HRchanges · EDGAR ↗
Q2 2023$18M2Aug 10, 202313F-HRchanges · EDGAR ↗
Q1 2023$83M3May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$128M5Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$229M6Nov 3, 202213F-HRchanges · EDGAR ↗
Q2 2022$244M7Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$369M7May 10, 202213F-HRchanges · EDGAR ↗
Q4 2021$400M7Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$527M7Nov 5, 202113F-HRchanges · EDGAR ↗
Q2 2021$573M7Aug 11, 202113F-HRchanges · EDGAR ↗
Q1 2021$791M7May 12, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.2B7Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.2B7Nov 6, 202013F-HRchanges · EDGAR ↗
Q2 2020$685M5Aug 7, 202013F-HRchanges · EDGAR ↗
Q1 2020$368M5May 11, 202013F-HRchanges · EDGAR ↗
Q4 2019$226M4Feb 5, 202013F-HRchanges · EDGAR ↗
Q3 2019$176M4Nov 4, 201913F-HRchanges · EDGAR ↗
Q2 2019$235M3Aug 6, 201913F-HRchanges · EDGAR ↗
Q1 2019$204M3May 3, 201913F-HRchanges · EDGAR ↗
Q4 2018$119M3Jan 28, 201913F-HRchanges · EDGAR ↗

Other Included Managers

This filing reports holdings on behalf of 3 additional managers.

  • Mark Levin028-18439
  • Kevin P. Starr028-18438
  • Robert I. Tepper028-18419

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.